SG11201807475VA - Glucono delta-lactone for treatment of vaginal fungal infections - Google Patents

Glucono delta-lactone for treatment of vaginal fungal infections

Info

Publication number
SG11201807475VA
SG11201807475VA SG11201807475VA SG11201807475VA SG11201807475VA SG 11201807475V A SG11201807475V A SG 11201807475VA SG 11201807475V A SG11201807475V A SG 11201807475VA SG 11201807475V A SG11201807475V A SG 11201807475VA SG 11201807475V A SG11201807475V A SG 11201807475VA
Authority
SG
Singapore
Prior art keywords
international
lactone
glucono
treatment
pct
Prior art date
Application number
SG11201807475VA
Inventor
Ulf Ellervik
Olov Sterner
Helena Strevens
Sophie Manner
Original Assignee
Gedea Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gedea Biotech Ab filed Critical Gedea Biotech Ab
Publication of SG11201807475VA publication Critical patent/SG11201807475VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27B—FURNACES, KILNS, OVENS, OR RETORTS IN GENERAL; OPEN SINTERING OR LIKE APPARATUS
    • F27B14/00—Crucible or pot furnaces
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27B—FURNACES, KILNS, OVENS, OR RETORTS IN GENERAL; OPEN SINTERING OR LIKE APPARATUS
    • F27B14/00—Crucible or pot furnaces
    • F27B14/06—Crucible or pot furnaces heated electrically, e.g. induction crucible furnaces with or without any other source of heat
    • F27B14/061—Induction furnaces
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27B—FURNACES, KILNS, OVENS, OR RETORTS IN GENERAL; OPEN SINTERING OR LIKE APPARATUS
    • F27B14/00—Crucible or pot furnaces
    • F27B14/08—Details peculiar to crucible or pot furnaces
    • F27B14/10—Crucibles
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27B—FURNACES, KILNS, OVENS, OR RETORTS IN GENERAL; OPEN SINTERING OR LIKE APPARATUS
    • F27B3/00—Hearth-type furnaces, e.g. of reverberatory type; Tank furnaces
    • F27B3/10—Details, accessories, or equipment peculiar to hearth-type furnaces
    • F27B3/12—Working chambers or casings; Supports therefor
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27D—DETAILS OR ACCESSORIES OF FURNACES, KILNS, OVENS, OR RETORTS, IN SO FAR AS THEY ARE OF KINDS OCCURRING IN MORE THAN ONE KIND OF FURNACE
    • F27D1/00—Casings; Linings; Walls; Roofs
    • F27D1/16—Making or repairing linings increasing the durability of linings or breaking away linings
    • F27D1/1626—Making linings by compacting a refractory mass in the space defined by a backing mould or pattern and the furnace wall
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/22—Furnaces without an endless core
    • H05B6/24—Crucible furnaces
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27B—FURNACES, KILNS, OVENS, OR RETORTS IN GENERAL; OPEN SINTERING OR LIKE APPARATUS
    • F27B14/00—Crucible or pot furnaces
    • F27B14/06—Crucible or pot furnaces heated electrically, e.g. induction crucible furnaces with or without any other source of heat
    • F27B14/061—Induction furnaces
    • F27B2014/066—Construction of the induction furnace
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27B—FURNACES, KILNS, OVENS, OR RETORTS IN GENERAL; OPEN SINTERING OR LIKE APPARATUS
    • F27B14/00—Crucible or pot furnaces
    • F27B14/08—Details peculiar to crucible or pot furnaces
    • F27B2014/0837—Cooling arrangements

Abstract

WO 171747 / 3 1 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/174731 Al 12 October 2017 (12.10.2017) WIPO I PCT 11111111111111011101010111110101111101110101110M0111110111011111111111110111111 Fig 4b 1A 1 1 0.8 0.6 4 0,2 G.0 (51) International Patent Classification: A61K 9/00 (2006.01) A61P 31/10 (2006.01) A61K 31/366 (2006.01) (21) International Application Number: PCT/EP2017/058268 (22) International Filing Date: 6 April 2017 (06.04.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1650467-2 6 April 2016 (06.04.2016) SE (71) Applicant: GEDEA BIOTECH AB [SE/SE]; c/o Saftiolm Partners AB, Ideon Science Park, 223 70 Lund (SE). (72) Inventors: ELLERVIK, Ulf; Lantvagen 48, 246 33 Lod- dekopinge (SE). STERNER, Olov; Giggatan 24, 212 42 Malmo (SE). STREVENS, Helena; Fjelievagen 15B, 227 36 Lund (SE). MANNER, Sophie; Sockengatan 100, 252 51 Helsingborg (SE). (74) Agent: STROM & GULLIKSSON AB; P.O. Box 4188, SE-203 13 MALMO (SE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: GLUCONO DELTA-LACTONE FOR TREATMENT OF VAGINAL FUNGAL INFECTIONS (57) : The present invention relates to a pharma- ceutical formulation for vaginal administration, wherein the formulation comprises a pharmaceutical acceptable excipi- ent and glucono S-lactone,wherein the glucono S-lactoneis present in an amount of 5 to 99 wt % of the formulation. The invention also relates to a pharmaceutical formulation according to the invention for use in the prevention or treat - T ment of a urogenital fungal infection. Furthermore, the in- vention relates to glucono S-lactone (formula (III)), for use in the in the prevention or treatment of a fungal infection. U)
SG11201807475VA 2016-04-06 2017-04-06 Glucono delta-lactone for treatment of vaginal fungal infections SG11201807475VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1650467 2016-04-06
PCT/EP2017/058268 WO2017174731A1 (en) 2016-04-06 2017-04-06 Glucono delta-lactone for treatment of vaginal fungal infections

Publications (1)

Publication Number Publication Date
SG11201807475VA true SG11201807475VA (en) 2018-10-30

Family

ID=58530540

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807475VA SG11201807475VA (en) 2016-04-06 2017-04-06 Glucono delta-lactone for treatment of vaginal fungal infections

Country Status (22)

Country Link
US (2) US10993907B2 (en)
EP (1) EP3439633B1 (en)
JP (1) JP6967785B2 (en)
KR (1) KR102346658B1 (en)
CN (1) CN109069413B (en)
AU (1) AU2017248050B2 (en)
BR (1) BR112018070370A2 (en)
CA (1) CA3013809C (en)
CL (1) CL2018002705A1 (en)
DK (1) DK3439633T3 (en)
EA (1) EA036748B1 (en)
ES (1) ES2896680T3 (en)
HU (1) HUE056303T2 (en)
IL (1) IL261796B (en)
MX (1) MX2018012210A (en)
MY (1) MY198473A (en)
PH (1) PH12018502131A1 (en)
PL (1) PL3439633T3 (en)
SG (1) SG11201807475VA (en)
UA (1) UA123954C2 (en)
WO (1) WO2017174731A1 (en)
ZA (1) ZA201804938B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7424636B2 (en) 2017-10-06 2024-01-30 ジェディア バイオテック エービー Gluconic acid derivatives for the treatment and/or prevention of microbial infections
US20220193031A1 (en) 2019-04-05 2022-06-23 Gedea Biotech Ab Vaginal Tablet Formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
US5942250A (en) * 1986-12-23 1999-08-24 Tristrata Technology, Inc. Compositions and methods for enhancing the topical effects of sunscreen agents
CN1051454C (en) * 1994-12-13 2000-04-19 周彦华 High-performance non-toxic vagina contraceptive
WO1999066904A1 (en) * 1998-06-25 1999-12-29 Theratech, Inc. INCORPORATION OF LATENT ACID SOLUBILIZING AGENTS IN COATED PELLET FORMULATIONS TO OBTAIN pH INDEPENDENT RELEASE
AT407111B (en) 1998-12-22 2000-12-27 Gergely Dr & Co SUGAR- AND / OR SUGAR-ALCOHOLIC MATRIX MATERIAL AND METHOD FOR THE PRODUCTION THEREOF
AUPP839499A0 (en) * 1999-01-29 1999-02-25 Australian National University, The A method for controlling plant pathogens, and agents useful for same
US20030017207A1 (en) * 2001-05-01 2003-01-23 Lin Shun Y. Compositions and methods for treating vulvovaginitis and vaginosis
US20060172007A1 (en) * 2001-05-01 2006-08-03 Nawaz Ahmad Compositions and methods for reducing vaginal pH
US20060105008A1 (en) 2002-03-28 2006-05-18 Nawaz Ahmad Compositions and methods for reducing vaginal pH
CN101703047A (en) 2002-08-12 2010-05-12 隆萨股份有限公司 antimicrobial compositions
US20040126369A1 (en) * 2002-12-30 2004-07-01 Richard Payne Delivery of peroxide-generating enzymes to the vaginal tract
US20070059278A1 (en) 2005-09-12 2007-03-15 Nawaz Ahmad Anhydrous composition containing an acid-acid buffer system
US20100104615A1 (en) 2006-12-15 2010-04-29 Ellen Ab Absorbent article comprising lactic acid producing bacteria
SI2142186T1 (en) 2007-03-30 2014-08-29 Laccure Ab Use of oligomers of lactic acid in the treatment of gynaecological infections
CN101808638B (en) 2007-09-05 2012-07-25 宝丽制药股份有限公司 Antifungal composition
JP2017509705A (en) 2014-03-20 2017-04-06 リー エバーティング，シェリル Compositions for the treatment of skin diseases and disorders

Also Published As

Publication number Publication date
DK3439633T3 (en) 2021-12-20
PL3439633T3 (en) 2022-01-10
UA123954C2 (en) 2021-06-30
CA3013809A1 (en) 2017-10-12
EP3439633B1 (en) 2021-09-15
IL261796B (en) 2021-06-30
US20190110983A1 (en) 2019-04-18
CA3013809C (en) 2024-01-02
EA036748B1 (en) 2020-12-16
CL2018002705A1 (en) 2018-11-30
KR20180127314A (en) 2018-11-28
JP2019510761A (en) 2019-04-18
HUE056303T2 (en) 2022-02-28
US10993907B2 (en) 2021-05-04
IL261796A (en) 2018-10-31
CN109069413B (en) 2022-09-27
BR112018070370A2 (en) 2019-01-29
US11696891B2 (en) 2023-07-11
MY198473A (en) 2023-08-31
PH12018502131A1 (en) 2019-09-16
MX2018012210A (en) 2018-12-17
ZA201804938B (en) 2022-03-30
JP6967785B2 (en) 2021-11-17
US20210212937A1 (en) 2021-07-15
EP3439633A1 (en) 2019-02-13
ES2896680T3 (en) 2022-02-25
KR102346658B1 (en) 2022-01-03
AU2017248050A1 (en) 2018-11-08
CN109069413A (en) 2018-12-21
EA201891744A1 (en) 2019-03-29
WO2017174731A1 (en) 2017-10-12
AU2017248050B2 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201901986SA (en) Process for the manufacture of a solid pharmaceutical adminstration form
SG11201810078PA (en) Stabilized pre-fusion rsv f proteins
SG11201903076QA (en) Carbamoyl phenylalaninol compounds and uses therof
SG11201804223TA (en) OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201903770UA (en) Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
SG11201906616VA (en) Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants
SG11201806424TA (en) Therapeutic compounds
SG11201810934TA (en) Microparticles comprising a sulphur-containing compound
SG11201807023QA (en) Compositions and methods for preventing and/or treating vitamin b12 deficiency